More than 70% of breast cancers contain lymphocytic infiltration in the stroma and preclinical studies suggest that immune-editing and partial control of cancer progression by the local immune microenvironment operates in most breast cancers. Consistent with this hypothesis, a large number of studies demonstrated a favorable prognostic and chemotherapy response predictive role for immune infiltration in breast cancer. The evidence is particularly strong for triple negative and HER2 positive cancers. The development of clinically effective immune checkpoint inhibitors now provides an opportunity to test the therapeutic potential of augmenting the local anti-tumor immune response. Several Phase I clinical trials using single agent anti-PD1 and anti-PDL1 antibodies demonstrated objective tumor response rates, with remarkably durable responses, in heavily pretreated, metastatic, triple negative cancers and somewhat lower responses in estrogen-receptor positive cancers. Currently, close to 50 ongoing, or soon to open, clinical trials evaluate the role of this new treatment modality in breast cancer.
from Cancer via ola Kala on Inoreader http://ift.tt/1RuYzWj
via IFTTT
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου